The therapeutic effect and immune-related adverse event of nivolmab in Anjo Kosei Hospital
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz343.079
Abstract: Abstract Background Nivolmab is approved as a novel immunocheckpoint inhibitor and peculiar immune-related adverse events (irAE) including interstitial lung disease (ILD), endocrinological disorder, and immunological colitis are reported. The rapid diagnosis and treatment are indispensable… read more here.
Keywords: immune related; therapeutic effect; effect; related adverse ... See more keywords